The NCI-MATCH: A National, Collaborative Precision Oncology Trial for Diverse Tumor Histologies.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer cell"
DOI: 10.1016/j.ccell.2020.12.021
Abstract: The NCI-MATCH is a national master protocol trial, published in the Journal of Clinical Oncology, in which diverse tumors are sequenced and patients assigned to treatment. The trial demonstrates the feasibility of identifying rare and… read more here.
Keywords: nci match; trial; match national; collaborative precision ... See more keywords
Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience.
Sign Up to like & getrecommendations! Published in 2017 at "Current problems in cancer"
DOI: 10.1016/j.currproblcancer.2017.05.003
Abstract: Next generation sequencing (NGS) technologies have been widely adapted in clinical oncology by utilizing the profiled genetic mutation information to select patients and to guide the choice of target therapy. To fulfill the regulatory compliance,… read more here.
Keywords: nci match; ngs assay; precision oncology; oncology ... See more keywords
Impact of NCI-MATCH: a Nationwide Oncology Precision Medicine Trial
Sign Up to like & getrecommendations! Published in 2019 at "Expert Review of Precision Medicine and Drug Development"
DOI: 10.1080/23808993.2019.1623023
Abstract: ABSTRACT Introduction: The National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) is a multicenter phase II tissue agnostic trial with 39 treatment arms, that matches a targeted drug to an actionable genetic alteration identified by… read more here.
Keywords: nci match; medicine; oncology; precision medicine ... See more keywords
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-3443
Abstract: Purpose: Substantial preclinical evidence and case reports suggest that MEK inhibition is an active approach in tumors with BRAF mutations outside the V600 locus, and in BRAF fusions. Thus, Subprotocol R of the NCI-MATCH study… read more here.
Keywords: braf; solid tumors; non v600; nci match ... See more keywords
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Sign Up to like & getrecommendations! Published in 2023 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-22-3334
Abstract: Abstract Over the past decade, multiple trials, including the precision medicine trial National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) have sought to determine if treating cancer based on specific genomic alterations is… read more here.
Keywords: nci match; trial; therapy; histology ... See more keywords
Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2019-ct139
Abstract: BACKGROUND: NCI-MATCH is a multi-cohort, signal finding trial that assigns pts with advanced cancers to targeted therapies based on central tumor genomic testing. Arm B evaluated afatinib, an ErbB family blocker, in pts with ERBB2… read more here.
Keywords: therapy; arm; tumor; nci match ... See more keywords
NCI-MATCH Sets "Benchmark of Actionability".
Sign Up to like & getrecommendations! Published in 2020 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2020-100
Abstract: The NCI Molecular Analysis for Therapy Choice trial has demonstrated the feasibility of sequencing tumor DNA and matching patients to targeted therapies according to their cancer's mutation profile. However, response rates of those assigned to… read more here.
Keywords: nci match; sets benchmark; benchmark actionability; match sets ... See more keywords
A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.3087
Abstract: 3087 Background: The NCI-MATCH trial assigns patients (pts) with solid tumors, lymphomas, or multiple myeloma to targeted therapies based on genetic alterations identified in tumor biopsies. Neurofibromatosis 2 (NF2)-inactivated tumors demonstrate increased sensitivity to FAK… read more here.
Keywords: response; defactinib; altered tumors; nf2 altered ... See more keywords